MedPath

The Effects of Oxytocin on Social Touch

Not Applicable
Conditions
Healthy
Interventions
Drug: intranasal placebo
Registration Number
NCT03278860
Lead Sponsor
University of Electronic Science and Technology of China
Brief Summary

The main aim of the study is to investigate whether intranasal oxytocin (24IU) can enhance hedonic experience and associated brain-reward reward responses to social touch.

Detailed Description

A double-blind, within-subject, placebo controlled design is employed in this study. In total 50 healthy male subjects will be recruited and they will come twice, once with the administration of oxytocin nasal spray and the other placebo (interval time is more than 2 weeks). 45 minutes after treatment subjects will be applied two different types of pleasant touch: social touch from a masseur (professional therapist) and non-social touch from a massage device. After each condition the subjects will be asked to rate pleasantness, likability, and arousal. Simultaneously functional brain activity will be acquired via fMRI. Blood samples will be taken before and after the intervention to assess oxytocin levels. All subjects were asked to complete a range of questionnaires measuring trait personality and mood: Beck Depression Inventory (BDI), Cheek and Buss Shyness Scale (CBSS),Autism Spectrum Quotient (ASQ), Empathy Quotient (EQ), NEO Five Factor Inventory (NEO-FFI), Liebowitz Social Anxiety Scale (LSAS),Behavioral Inhibition System and Behavioral Activation System Scale (BISBAS),Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ),State-Trait Anxiety Inventory (STAI), Social Touch Questionnaire (STQ), Sensory over Responsivity Scale (SOR) and Under Responsivity Scale (URS) one day before the first scanning. On the first and second scanning day, the subjects were asked to complete Positive and Negative Affect Schedule (PANAS) before and after treatment administration.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
50
Inclusion Criteria
  • Healthy subjects without any past or present psychiatric or neurological disorders
Exclusion Criteria
  • History of brain injury
  • Medical or mental illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Placebo then oxytocinintranasal placeboParticipants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
Oxytocin then placebointranasal oxytocinParticipants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
Oxytocin then placebointranasal placeboParticipants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
Placebo then oxytocinintranasal oxytocinParticipants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
Primary Outcome Measures
NameTimeMethod
Neural indices: fMRI-based measures of interoceptive and reward processing45-90 minutes after treatment administration

fMRI-based measures of social and non-social touch-related brain activity

Secondary Outcome Measures
NameTimeMethod
Behavioral index: pleasantness experience45-90 minutes after treatment administration

Ratings for pleasantness during the application of social and non-social touch

Behavioral index: likability experience45-90 minutes after treatment administration

Ratings for likability during the application of social and non-social touch

Behavioral index: arousal experience45-90 minutes after treatment administration

Ratings for arousal during the application of social and non-social touch

Trial Locations

Locations (1)

University of Electronic Science and Technology of China(UESTC)

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath